NCT04129268

Brief Summary

In 2015, there were 415 million adults worldwide with type II diabetes and by 2040, typeII diabetes will affect one in ten adults worldwide. Type II diabetes reduces quality of life and total lifespan, and two of the best countermeasures to type II diabetes are not drugs, but diet and exercise. Several studies have investigated the effects of exercise modality (aerobic, resistance, or concurrent) on glycaemic control and the mechanisms of these benefits. However, the minimal 'dose' of exercise required to increase insulin sensitivity and improve glycaemic control has never been established. Secondly, there is a progressive loss of muscle structure and function with age, which is known as sarcopenia. This study will also investigate whether the minimal amount of exercise is influenced by biological age and muscle mass by comparing physiological and biochemical responses in BMI-matched young and old volunteers. This study will therefore provide pilot data on the effect of age on exercise-mediated glycaemic control.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
21

participants targeted

Target at below P25 for not_applicable type-2-diabetes

Timeline
Completed

Started Oct 2019

Typical duration for not_applicable type-2-diabetes

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2019

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

October 9, 2019

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 16, 2019

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 26, 2022

Completed
3 days until next milestone

Study Completion

Last participant's last visit for all outcomes

September 29, 2022

Completed
Last Updated

May 22, 2023

Status Verified

May 1, 2023

Enrollment Period

3 years

First QC Date

October 9, 2019

Last Update Submit

May 19, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Lowering of blood glucose values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities

    The investigators will quantify the lowering of blood glucose values during the OGTT 24h following 175kcal, 350kcal and 700kcal exercise when compared to a no exercise control.

    over the 8 weeks of participant involvement in study

Secondary Outcomes (1)

  • Lowering of serum insulin values throughout the two-hour oral glucose tolerance test (OGTT) measured every 30 minutes throughout from an arterialised-venous hand vein 24 hours following large (700kcal) in comparison to small (175kcal) exercise quantities

    over the 8 weeks of participant involvement in study

Study Arms (4)

No exercise control

OTHER

The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis.

Other: Cycle ergometry exercise at 60% VO2max

175kcal Cycle ergometry exercise at 60% VO2max

EXPERIMENTAL

The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis.

Other: Cycle ergometry exercise at 60% VO2max

350kcal Cycle ergometry exercise at 60% VO2max

EXPERIMENTAL

The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis.

Other: Cycle ergometry exercise at 60% VO2max

700kcal Cycle ergometry exercise at 60% VO2max

EXPERIMENTAL

The investigators will use a randomised, crossover design study, where all subjects will complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer the day before an oral glucose tolerance test (OGTT). 350kcal has previously been shown to improve control of blood glucose when an OGTT is competed 24 h after the cycle ergometry exercise. The investigators have therefore chosen half this amount (175kcal) and double this amount (700kcal) to try and stimulate the greatest (700kcal) and least (175kcal) improvements in glycaemic control compared to no exercise. The investigators are, in essence, calculating a dose-response curve for quantity of exercise ((i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; and (iv) 700kcal exercise on a cycle ergometer) on the x axis and improvement in glycaemic control on the y axis.

Other: Cycle ergometry exercise at 60% VO2max

Interventions

Participants visit the lab on four occasions to complete (i) no exercise; (ii) 175kcal exercise; (iii) 350kcal exercise; (iv) or 700kcal exercise (randomised).

175kcal Cycle ergometry exercise at 60% VO2max350kcal Cycle ergometry exercise at 60% VO2max700kcal Cycle ergometry exercise at 60% VO2maxNo exercise control

Eligibility Criteria

Age18 Years - 80 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged 18 years and upwards
  • Capacity to consent to participation
  • Diagnosis of type II diabetes
  • BMI \>25

You may not qualify if:

  • Patient is aged under 18 years
  • Patient lacks capacity to consent to participation
  • Anything that investigators feel affects the study measurements or safety
  • Cohort 2: 9 young control subjects under the following criteria:
  • Aged 18 - 40
  • Capacity to consent to participation
  • BMI \>25
  • Subject is aged under 18 years
  • Subject lacks capacity to consent to participation
  • Subject on medication that affects glycaemic control
  • Anything that investigators feel affects the study measurements or safety
  • Cohort 3: 9 older control subjects under the following criteria:
  • Aged \>60
  • Capacity to consent to participation
  • BMI \>25
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Royal Lancaster Infirmary

Lancaster, United Kingdom

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator and Lecturer in Sports Science

Study Record Dates

First Submitted

October 9, 2019

First Posted

October 16, 2019

Study Start

October 1, 2019

Primary Completion

September 26, 2022

Study Completion

September 29, 2022

Last Updated

May 22, 2023

Record last verified: 2023-05

Data Sharing

IPD Sharing
Will not share

Locations